ACE2 and COVID-19: Administration of type I IFN has been proposed as a strategy for COVID-19 intervention (33); however, it must be noted that type I IFN signaling has been shown to elevate angiotensin-converting enzyme 2 (ACE2) expression (34) in lung cells, which can potentially lead to enhanced infection.